Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized,active-controlled DURATION-8 study期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized,active-controlled DURATION-8 study

Authors:	Ele Ferrannini MD Simona Baldi PhD Juan P Frías MD Cristian Guja MD Elise Hardy MD Enrico Repetto MD Serge A Jabbour MD Ralph A DeFronzo MD

Institution:	1. CNR Institute of Clinical Physiology, Pisa, Italy;2. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy;3. National Research Institute, Los Angeles, California;4. Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania;5. AstraZeneca, Gaithersburg, Maryland;6. Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania;7. Diabetes Division, University of Texas Health Science Center, San Antonio, Texas

Abstract:

Keywords:	combination therapy dapagliflozin exenatide glucagon-like peptide-1 agonist glycaemic control sodium-glucose co-transporter-2 inhibitor